Eli Lilly
Lilly’s Tirzepatide Wins NICE Endorsement for Obesity Treatment with BMI and Weight Loss Conditions
Lilly, tirzepatide, NICE endorsement, obesity treatment, BMI, weight loss, Zepbound, Mounjaro, GLP-1 receptor agonist
Lilly Touts Fibrosis Win, Strengthens Case for Tirzepatide in MASH Treatment
Eli Lilly, Tirzepatide, MASH, Fibrosis, Liver Disease, Obesity, Diabetes, GLP-1/GIP Dual Agonist
Lilly Initiates Search for New CFO Following Anat Ashkenazi’s Departure to Alphabet
Anat Ashkenazi, CFO, Eli Lilly, Alphabet, Google, Ruth Porat, Sundar Pichai, Financial Leadership, Biopharma, Tech Industry
Lilly’s Tirzepatide Demonstrates Efficacy in Mid-Stage MASH Study
Tirzepatide, MASH, Eli Lilly, Fibrosis, Liver Disease, Diabetes, Obesity
Structure Therapeutics’ Oral GLP-1 Achieves Comparable Weight Loss to Lilly’s Candidate
Structure Therapeutics, GLP-1, Obesity, Weight Loss, Lilly, Oral Candidate
Lilly Strengthens Neuro Pipeline with $45M Deal for QurAlis’ Preclinical ALS and Dementia Treatment
Lilly, QurAlis, ALS, dementia, neurodegenerative diseases, UNC13A, splice-switching antisense oligonucleotide, QRL-204, neuro pipeline, preclinical treatment
Eli Lilly Invests $5.3 Billion in Indiana Plant to Boost Diabetes and Obesity Drug Production ###
Eli Lilly, Diabetes, Obesity, Mounjaro, Zepbound, Tirzepatide, Indiana, Manufacturing, API, Novo Nordisk, GLP-1 drugs
Regulatory Tracker: Lilly’s Retevmo Secures Pediatric Cancer FDA Nod ###
Retevmo, Eli Lilly, FDA approval, pediatric cancer, RET-altered, thyroid cancer, solid tumors, accelerated approval, LIBRETTO-121 trial, selpercatinib
Lilly Expands Radiopharmaceutical Portfolio with Aktis Acquisition
Lilly, Aktis, radiopharmaceutical, acquisition, portfolio, cancer therapy, targeted treatment
Lilly’s Weekly Insulin Therapy Excels in Two Major Clinical Trials, Narrowing Gap with Novo Nordisk
Lilly, Novo Nordisk, weekly insulin, primary endpoint, pivotal trials, diabetes management, insulin therapy, clinical trials, diabetes treatment, pharmaceutical industry.